A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis

Björn Evertsson; Tammy Hoyt; Angel Christensen; Faiez Al Nimer; John Foley; Fredrik Piehl

doi:10.1177/2055217320964505

A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis

Mult Scler J Exp Transl Clin. 2020 Oct 12;6(4):2055217320964505. doi: 10.1177/2055217320964505. eCollection 2020 Oct-Dec.

Authors

Björn Evertsson¹, Tammy Hoyt¹, Angel Christensen², Faiez Al Nimer¹, John Foley², Fredrik Piehl¹

Affiliations

¹ Neuroimmunology Unit, Karolinska Institutet, Clinical Neuroscience, Karolinska University Hospital, Stockholm, Sweden.
² Rocky Mountain Multiple Sclerosis Clinic, Neurology, Salt Lake City, UT, USA.

Abstract

Background: Rituximab (RTX) and ocrelizumab (OCR) are two anti-CD20 biologics used in MS; however, comparisons on safety and efficacy are rare.

Objective: To compare treatment outcomes over the first year with RTX and OCR.

Methods: Retrospective cohort study comprising MS patients initiating RTX at the Karolinska University Hospital (Sweden; n = 311) and OCR at Rocky Mountain MS Clinic (Utah, USA; n = 161), respectively.

Results: Levels of immunoglobulin G measured in blood dropped 0.16 g/L (95% confidence interval 0.01 to 0.31) with each OCR infusion, but remained stable with RTX. In contrast, levels of immunoglobulin M decreased to a similar extent with both drugs. Ten and 15% of patients discontinued treatment with RTX and OCR, respectively (n.s), however, adverse events leading to treatment discontinuation were more common with OCR (6.8% vs 2.6%; p = 0.026). Only 3.1 and 1.6% discontinued OCR and RTX, respectively, due to lack of effect (n.s). The degree of B cell depletion was superior with OCR.

Conclusion: Overall, differences between the two treatments were small. Although the study design precludes robust conclusions regarding the risk-benefit with the studied therapies, our findings indicate that the tolerability and safety with RTX is not inferior to OCR.

Keywords: Multiple sclerosis; biomarkers; immunoglobulins; ocrelizumab; relapsing/remitting; rituximab.